09:45 EDT Oncternal Therapeutics trading resumes
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCT:
- Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
- Oncternal terminates ONCT-534, ONCT-808 studies, explores strategic alternatives
- Oncternal Therapeutics trading halted, news pending
- Oncternal Therapeutics price target lowered to $18 from $19 at H.C. Wainwright
- Oncternal Therapeutics reports Q2 EPS ($2.89 ), consensus ($3.10)